Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Female Contraception Overview | 8 | 1 |
| Therapeutics Development | 9 | 2 |
| Pipeline Products for Female Contraception Overview | 9 | 1 |
| Pipeline Products for Female Contraception Comparative Analysis | 10 | 1 |
| Female Contraception Therapeutics under Development by Companies | 11 | 1 |
| Female Contraception Therapeutics under Investigation by Universities/Institutes | 12 | 1 |
| Female Contraception Pipeline Products Glance | 13 | 3 |
| Late Stage Products | 13 | 1 |
| Clinical Stage Products | 14 | 1 |
| Early Stage Products | 15 | 1 |
| Female Contraception Products under Development by Companies | 16 | 1 |
| Female Contraception Products under Investigation by Universities/Institutes | 17 | 1 |
| Female Contraception Companies Involved in Therapeutics Development | 18 | 5 |
| Agile Therapeutics, Inc. | 18 | 1 |
| ANI Pharmaceuticals, Inc. | 19 | 1 |
| Evofem, Inc. | 20 | 1 |
| Mithra Pharmaceuticals S.A. | 21 | 1 |
| Orbis Biosciences, Inc. | 22 | 1 |
| Female Contraception Therapeutics Assessment | 23 | 10 |
| Assessment by Monotherapy Products | 23 | 1 |
| Assessment by Combination Products | 24 | 1 |
| Assessment by Target | 25 | 2 |
| Assessment by Mechanism of Action | 27 | 2 |
| Assessment by Route of Administration | 29 | 2 |
| Assessment by Molecule Type | 31 | 2 |
| Drug Profiles | 33 | 27 |
| (drospirenone + estetrol) Drug Profile | 33 | 2 |
| (estradiol acetate + nestorone) Drug Profile | 35 | 2 |
| (estradiol acetate + prasterone + progesterone) Drug Profile | 37 | 2 |
| AG-200 ER Drug Profile | 39 | 1 |
| AG-200 SP Drug Profile | 40 | 1 |
| AG-20015 Drug Profile | 41 | 4 |
| Amphora Drug Profile | 45 | 2 |
| etonogestrel ER Drug Profile | 47 | 1 |
| EVE-106 Drug Profile | 48 | 1 |
| levonorgestrel Drug Profile | 49 | 2 |
| LJ-102 Drug Profile | 51 | 1 |
| Monoclonal Antibody Conjugates for Contraception Drug Profile | 52 | 1 |
| NOV-1003 Drug Profile | 53 | 1 |
| S-003296 Drug Profile | 54 | 1 |
| S-0101255 Drug Profile | 55 | 1 |
| Small Molecule 1 for Fertility Control Drug Profile | 56 | 1 |
| Small Molecule 2 for Fertility Control Drug Profile | 57 | 1 |
| Small Molecule to Modulate Progesterone Receptor for Fertility Control Drug Profile | 58 | 1 |
| Synthetic Peptides for Contraception Drug Profile | 59 | 1 |
| Female Contraception Dormant Projects | 60 | 2 |
| Female Contraception Discontinued Products | 62 | 1 |
| Female Contraception Product Development Milestones | 63 | 9 |
| Featured News &Press Releases | 63 | 1 |
| Apr 05, 2016: FDA Feedback On Spa Estelle: A New Step Closer To The Launch Of Estelle Phase III Pivotal Clinical Studies | 63 | 1 |
| Apr 01, 2016: Topline Results Of Food Effect Study Of The Product Candidate Estelle, The New Combined Oral Contraceptive Composed Of 15 mg Of Estetrol (E4) And 3 mg Of Drospirenone | 63 | 1 |
| Mar 24, 2016: Already 4 European Countries Fully Approved Protocol Of MIT-ES001-C301 Estelle Phase III Clinical Study | 64 | 1 |
| Oct 19, 2015: Agile Therapeutics Announces Completion of Patient Enrollment in Twirla Phase 3 SECURE Clinical Trial | 64 | 1 |
| Oct 19, 2015: Agile Therapeutics Announces Completion of Patient Enrollment in Twirla Phase 3 SECURE Clinical Trial | 65 | 1 |
| Sep 22, 2015: Evofem Announces FDA Acceptance of New Drug Application for Amphora as a Contraceptive | 65 | 1 |
| Aug 31, 2015: Agile Therapeutics Announces Completion of Patient Recruitment in Twirla Phase 3 SECURE Clinical Trial | 66 | 1 |
| Aug 26, 2015: The European Journal Of Contraception And Reproductive Health Care Publishes Two Scientific Articles About E4 (Estetrol) Dinox Phase II Study: Two Of The Most Read Papers By The Scientific Community | 67 | 1 |
| Jul 13, 2015: Aquila Solutions,Partners with Evofem to Submit New Drug Application to U.S. FDA for Amphora as a Contraceptive | 68 | 1 |
| Jul 06, 2015: Evofem Submits New Drug Application to U.S. FDA for Amphora as a Contraceptive | 68 | 1 |
| Jan 13, 2015: Evofem Announces Pre-NDA Meeting With FDA for Amphora | 69 | 1 |
| Dec 01, 2014: Agile Therapeutics Announces Publication of Data on Low-Dose Investigational Contraceptive Patch | 69 | 1 |
| Sep 29, 2014: Agile Announces Dosing of First Patients in Twirla Phase 3 SECURE Study | 69 | 1 |
| Sep 16, 2014: Agile Initiates Phase 3 SECURE Study for Twirla | 70 | 1 |
| Jul 17, 2014: Agile Therapeutics Announces Allowance of Additional Patent Claims for Skinfusion | 70 | 2 |
| Appendix | 72 | 2 |
| Methodology | 72 | 1 |
| Coverage | 72 | 1 |
| Secondary Research | 72 | 1 |
| Primary Research | 72 | 1 |
| Expert Panel Validation | 72 | 1 |
| Contact Us | 72 | 1 |
| Disclaimer | 73 | 1 |